Suresh Durgam, MD

Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, New Jersey

  • 9Articles
  • 70.3KReads
  • 2014–2025Active
  • 37Collaborators
  • 460Citations

About

Suresh Durgam, MD is affiliated with Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, New Jersey. Suresh Durgam has authored or co-authored 9 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2014 and 2025. Their work focuses on Schizophrenia/Schizoaffective Disorders, Anxiety, Bipolar Disorder, Depression (MDD), and Anxiolytics.

Publications

JCP
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
Original Research

Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial

August 25, 2025

In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
, , , et al
JCP
Efficacy of Lumateperone in Bipolar Depression With Mixed Features
Original Research

Efficacy of Lumateperone in Bipolar Depression With Mixed Features

April 24, 2023

Lumateperone significantly improved depression symptoms, disease severity, and quality of life in patients with bipolar depression with mixed features.
, , , et al
JCP
NNT, NNH, and LHH for Lumateperone
Original Research

NNT, NNH, and LHH for Lumateperone

March 6, 2023

The benefit-risk assessment of lumateperone was favorable as measured by number-needed-to-treat and number-needed-to-harm analyses.
, , , et al
JCP
Original Research

Vilazodone in Generalized Anxiety Disorder

December 28, 2016

The worries that characterize generalized anxiety disorder are so pervasive and excessive that they distort cognition and create a considerable burden of illness. See what the authors of this...
, , , et al
PCC
Article

Vilazodone and Psychic and Somatic Anxiety

April 28, 2016

Is the SSRI vilazodone effective for treating generalized anxiety disorder? To comprehensively evaluate the effect of vilazodone across the range of anxiety symptoms associated with the disorder, Khan and...
, , , et al
JCP
Original Research

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder

March 23, 2016

, , , et al
JCP
Original Research

The Effect of Cariprazine on Hostility Associated With Schizophrenia: Post Hoc Analyses From 3 Randomized Controlled Trials

January 27, 2016

, , , et al
JCP
Original Research

Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial

December 23, 2015

, , , et al
JCP
Original Research

Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

November 25, 2014

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe